Prevention

Feature Article

ASPREE Trial: Aspirin Associated With Higher Mortality, Hemorrhage Risk in Older Adults

ASPREE Trial: Aspirin Associated With Higher Mortality, Hemorrhage Risk in Older Adults

The use of aspirin in healthy elderly patients as a preventative strategy was associated with no prolongation of long-term disability-free survival compared with placebo.

Latest Features

ASPREE Trial: Aspirin Associated With Higher Mortality, Hemorrhage Risk in Older Adults

ASPREE Trial: Aspirin Associated With Higher Mortality, Hemorrhage Risk in Older Adults

The use of aspirin in healthy elderly patients as a preventative strategy was associated with no prolongation of long-term disability-free survival compared with placebo.

Assessing the Evidence of Aspirin for Primary Prevention in Diabetes

Assessing the Evidence of Aspirin for Primary Prevention in Diabetes

The substantial burden of cardiovascular disease in patients with diabetes has led to the exploration of various cardiovascular disease prevention strategies, including the use of aspirin.

Hypertension Disorders in Pregnancy: The Potential of Prophylactic Aspirin

Hypertension Disorders in Pregnancy: The Potential of Prophylactic Aspirin

To aid in the prevention of preeclampsia, American College of Obstetricians and Gynecologists and the US Preventive Services Task Force recommend low-dose aspirin prophylaxis in patients with 1 or more high-risk factors.

Managing Cardiovascular Risk in Rheumatoid Cachexia

Managing Cardiovascular Risk in Rheumatoid Cachexia

Because of the increased risk for cardiovascular disease in patients with rheumatoid arthritis, the increase in fat mass caused by rheumatoid cachexia can be especially concerning.

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Clinician Perspective: Examining the Link Between Antipsychotics and Diabetes

Endocrinologist Kevin M. Pantalone, DO, and psychiatrist Christian Kohler, MD, discuss the risk associated with the use of antipsychotic medications in individuals with type 2 diabetes.

How Many Chances Are Too Many? Treating Recurrent Infective Endocarditis in IV Drug Users

How Many Chances Are Too Many? Treating Recurrent Infective Endocarditis in IV Drug Users

How many second chances should a drug user get? As many as it takes for us — physicians, society, government, and the healthcare system — to get it right.

The Unintended Consequences of Cigarette Taxation

The Unintended Consequences of Cigarette Taxation

Although cigarette taxes were supposedly implemented to encourage smokers to quit, they can have a disproportionate effect on people of low-income status.

Breathing New Life Into COPD and Asthma Therapy With Statins

Breathing New Life Into COPD and Asthma Therapy With Statins

Statins have anti-inflammatory and anti-oxidative effects, which could reduce exacerbations of both asthma and chronic obstructive pulmonary disease.

AHA Examines CVD and Breast Cancer Relationship

AHA Examines CVD and Breast Cancer Relationship

The American Heart Association has released a scientific statement examining the relationship between cardiovascular disease and breast cancer.

The Mounting Evidence Against Electronic Cigarette Use

The Mounting Evidence Against Electronic Cigarette Use

Electronic cigarettes were once thought to be a helpful smoking cessation tool, but new evidence suggests they may be as if not more harmful than combustible cigarettes.

Latest News

FDA Publishes Final Guidance on Heparin-Containing Devices

FDA Publishes Final Guidance on Heparin-Containing Devices

The intent of the document is to help reduce heparin product overdose errors caused by misinterpretation of the drug strength displayed in the labeling.

Cardiac Changes Linked With Specific ARVs in Perinatally Acquired HIV

Cardiac Changes Linked With Specific ARVs in Perinatally Acquired HIV

Individual antiretroviral medications have been linked with changes in cardiac structure in youths with perinatally acquired HIV.

FDA to Review Praluent as Potential Treatment for MACE Risk Reduction

FDA to Review Praluent as Potential Treatment for MACE Risk Reduction

The sBLA is supported by data from the Phase 3 ODYSSEY OUTCOMES trial which included 18,924 patients who had experienced an acute coronary syndrome (ACS) in the previous 12 months.

FDA Grants Breakthrough Device Designation to Bloodless Hyperkalemia Test

FDA Grants Breakthrough Device Designation to Bloodless Hyperkalemia Test

The KardiaK Platform works through a deep neural network trained to detect hyperkalemia based on data from electrocardiograms (ECG) similar to those captured by the Company's KardiaMobile and KardiaBand devices.

Biologic Use Linked to Reduced Cardiovascular Risk in Inflammatory Arthritis

Biologic Use Linked to Reduced Cardiovascular Risk in Inflammatory Arthritis

Current biologic use was associated with a reduction in major cardiovascular events in patients with inflammatory arthritis.

Tiotropium Associated With Increased Cardiovascular Risk in COPD

Tiotropium Associated With Increased Cardiovascular Risk in COPD

Cardiovascular risk within 30 days of therapy start was approximately 2-fold higher with the incident use of tiotropium in COPD.

Cardiovascular Health Risks Identified With Diclofenac Use

Cardiovascular Health Risks Identified With Diclofenac Use

To investigate the cardiovascular risks associated with diclofenac, researchers conducted a series of cohort studies mimicking the design criteria of a clinical trial.

Age at Onset of Type 1 Diabetes Effects Mortality and Cardiovascular Complications

Age at Onset of Type 1 Diabetes Effects Mortality and Cardiovascular Complications

Investigators examine whether age of onset of type 1 diabetes affects mortality and cardiovascular risk.

IL-6 Receptor Polymorphisms May Be Associated With Aortic Aneurysm Risk

IL-6 Receptor Polymorphisms May Be Associated With Aortic Aneurysm Risk

Identification of interleukin 6 receptor single-nucleotide polymorphisms was associated with a significantly reduced risk for aortic aneurysm phenotypes.

Does Aspirin Cut the Risk of Initial Vascular Events in Patients at Moderate CVD Risk?

Does Aspirin Cut the Risk of Initial Vascular Events in Patients at Moderate CVD Risk?

For this double-blind, placebo-controlled study, researchers selected male patients ≥55 years and female patients ≥60 years with average cardiovascular risk and assigned them to enteric-coated aspirin 100mg (N=6270) or placebo (N=6276) once daily; the median follow-up time was 60 months.

Sign Up for Free e-Newsletters